Maxion Technologies

Maxion Therapeutics is a UK-based drug discovery company focused on developing innovative biologics for ion channels and G protein-coupled receptors (GPCRs). The company leverages its proprietary KnotBody platform, which fuses cystine-knot miniproteins (knottins) into antibody scaffolds to achieve high potency and selectivity against traditionally 'undruggable' cell-surface targets. Maxion's pipeline primarily targets autoimmune diseases and chronic pain, addressing significant unmet needs in these therapeutic areas. Led by pioneers in antibody engineering, the company is advancing several pre-clinical programs toward the clinic. The technology originated from IONTAS and was further developed to overcome the limitations of small molecule and traditional antibody approaches to ion channel modulation.